← Back to patent-cliff list
cRGD-ZW800-1
Tier C — Watch / tradecRGD-ZW800-1
Curadel
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Not applicable
Indications (approved)：Head and neck squamous cell carcinoma, Cholangiocarcinoma, Pancreatic cancer
Regional status
US
-
EU
Phase II
2022-11-09
China
-
Japan
-
Synthetic routes & intermediates4 routes
Originator routes × 0Optimised (non-patent) × 4Process routes × 0
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
OptimisedRoute 1Steps 4 · Total yield /
(I)819152-1-a98-71-5(II)819152-1-a563-80-4(IIIa)819152-1-a184351-56-2(IIIb)819152-1-a132557-72-3(IV)819152-1-a3779-42-8(V)819152-1-a—(VI)819152-1-a108-94-1(VII)819152-1-a—(VIII)819152-1-a—(IX)819152-1-a—(X)819152-1-a501-97-3(XI)819152-1-a,(XI)819152-1-b2412139-24-1API · cRGD-ZW800-1
| Code | CAS No. | Intermediate |
|---|---|---|
| (I)819152-1-a | 98-71-5 | 4-Hydrazinobenzenesulfonic acid |
| (II)819152-1-a | 563-80-4 | 2-Acetylpropane |
| (IIIa)819152-1-a | 184351-56-2 | Potassium 2,3,3-trimethyl-3H-indole-5-sulfonate |
| (IIIb)819152-1-a | 132557-72-3 | 2,3,3-Trimethyl-3H-indole-5-sulfonic acid |
| (IV)819152-1-a | 3779-42-8 | 3-Bromo-N,N,N-trimethylpropan-1-aminium bromide |
| (V)819152-1-a | - | 2,3,3-Trimethyl-5-sulfo-1-[3-(trimethylazaniumyl)propyl]-3H-indol-1-ium dibromide |
| (VI)819152-1-a | 108-94-1 | 4-Cyclohexanone |
| (VII)819152-1-a | - | [3-(Anilinomethylidene)-2-chlorocyclohex-1-en-1-yl]-N-phenylmethaniminium chloride |
| (VIII)819152-1-a | - | 2-[2-[2-Chloro-3-[2-[3,3-dimethyl-5-sulfonato-1-[3-(trimethylazaniumyl)propyl]-1,3-dihydro-2H-indol-2-ylidene]ethylidene]cyclohex-1-en-1-yl]ethenyl]-3,3-dimethyl-1-[3-(trimethylazaniumyl)propyl]-3H-indol-1-ium-5-sulfonate sodium bromide (1/2/3) |
| (IX)819152-1-a | - | Disodium 3-(4-oxidophenyl)propanoate |
| (X)819152-1-a | 501-97-3 | 3-(4-Hydroxyphenyl)propionic acid |
| (XI)819152-1-a,(XI)819152-1-b | 2412139-24-1 | 3-[4-[[6-[2-[3,3-dimethyl-5-sulfonato-1-[3-(trimethylazaniumyl)propyl]-1,3-dihydro-2H-indol-2-ylidene]ethylidene]-2-[2-[3,3-dimethyl-5-sulfonato-1-[3-(trimethylazaniumyl)propyl]-3H-indol-1-ium-2-yl]ethenyl]cyclohex-1-en-1-yl]oxy]phenyl]propanoate trifluoroacetic acid |
OptimisedRoute 2Steps 2 · Total yield /
(IIIb)819152-1-a132557-72-3(XI)819152-1-a,(XI)819152-1-b2412139-24-1(XII)819152-1-b—(XIII)819152-1-b,(XIII)819152-1-d217099-14-4API · cRGD-ZW800-1
| Code | CAS No. | Intermediate |
|---|---|---|
| (IIIb)819152-1-a | 132557-72-3 | 2,3,3-Trimethyl-3H-indole-5-sulfonic acid |
| (XI)819152-1-a,(XI)819152-1-b | 2412139-24-1 | 3-[4-[[6-[2-[3,3-dimethyl-5-sulfonato-1-[3-(trimethylazaniumyl)propyl]-1,3-dihydro-2H-indol-2-ylidene]ethylidene]-2-[2-[3,3-dimethyl-5-sulfonato-1-[3-(trimethylazaniumyl)propyl]-3H-indol-1-ium-2-yl]ethenyl]cyclohex-1-en-1-yl]oxy]phenyl]propanoate trifluoroacetic acid |
| (XII)819152-1-b | - | 2-[2-[3-[2-[3,3-Dimethyl-5-sulfonato-1-[3-(trimethylazaniumyl)propyl]-1,3-dihydro-2H-indol-2-ylidene]ethylidene]-2-(4-[3-[(2,5-dioxopyrrolidin-1-yl)oxy]-3-oxopropyl]phenoxy)cyclohex-1-en-1-yl]ethenyl]-3,3-dimethyl-1-[3-(trimethylazaniumyl)propyl]-3H-indol-1-ium-5-sulfonate sodium bromide (1/2/2) |
| (XIII)819152-1-b,(XIII)819152-1-d | 217099-14-4 | Cyclo(L-arginylglycyl-L-alpha-aspartyl-D-tyrosyl-L-lysyl) |
OptimisedRoute 3Steps 5 · Total yield /
(XIV)819152-1-c—(XIX)819152-1-c—(XV)819152-1-c—(XVI)819152-1-c154445-77-9(XVII)819152-1-c—(XVIII)819152-1-c71989-26-9(XX)819152-1-c118488-18-9(XXI)819152-1-c—(XXII)819152-1-c71989-14-5(XXIII)819152-1-c,(XXIII)819152-1-d—API · cRGD-ZW800-1
| Code | CAS No. | Intermediate |
|---|---|---|
| (XIV)819152-1-c | - | Resin bound [([[(9H-Fluoren-9-yl)methoxy]carbonyl]amino)acetyl]oxy |
| (XIX)819152-1-c | - | Resin bound N-[(2S)-2-[[N6-(tert-butoxycarbonyl)-L-lysyl]oxy]-5-[N'-(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-sulfonyl)carbamimidamido]pentanoyl]glycine |
| (XV)819152-1-c | - | Resin bound glycine |
| (XVI)819152-1-c | 154445-77-9 | (2S)-2-{[(9H-Fluoren-9-ylmethoxy)carbonyl]amino}-5-[2-(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-sulfonyl)carbamimidamido]pentanoic acid |
| (XVII)819152-1-c | - | Resin bound N5-[N-(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-sulfonyl)carbamimidoyl]-L-ornithylglycine |
| (XVIII)819152-1-c | 71989-26-9 | (2S)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid |
| (XX)819152-1-c | 118488-18-9 | Fmoc-O-tert-butyl-D-tyrosine |
| (XXI)819152-1-c | - | Resin bound (2S)-1-[(carboxymethyl)amino]-1-oxo-5-[N'-(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-sulfonyl)carbamimidamido]pentan-2-yl O-tert-butyl-D-tyrosyl-N6-(tert-butoxycarbonyl)-L-lysinate |
| (XXII)819152-1-c | 71989-14-5 | (2S)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid |
| (XXIII)819152-1-c,(XXIII)819152-1-d | - | Resin bound (5S,8S,11R,14S)-14-amino-8-[4-[(tert-butoxycarbonyl)amino]butyl]-11-[(4-tert-butoxyphenyl)methyl]-18,18-dimethyl-4,7,10,13,16-pentaoxo-5-[3-[N'-(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-sulfonyl)carbamimidamido]propyl]-6,17-dioxa-3,9,12-triazanonadecan-1-oic acid |
OptimisedRoute 4Steps 3 · Total yield /
(XIII)819152-1-b,(XIII)819152-1-d217099-14-4(XXIII)819152-1-c,(XXIII)819152-1-d—(XXIV)819152-1-d—(XXV)819152-1-d—API · cRGD-ZW800-1
| Code | CAS No. | Intermediate |
|---|---|---|
| (XIII)819152-1-b,(XIII)819152-1-d | 217099-14-4 | Cyclo(L-arginylglycyl-L-alpha-aspartyl-D-tyrosyl-L-lysyl) |
| (XXIII)819152-1-c,(XXIII)819152-1-d | - | Resin bound (5S,8S,11R,14S)-14-amino-8-[4-[(tert-butoxycarbonyl)amino]butyl]-11-[(4-tert-butoxyphenyl)methyl]-18,18-dimethyl-4,7,10,13,16-pentaoxo-5-[3-[N'-(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-sulfonyl)carbamimidamido]propyl]-6,17-dioxa-3,9,12-triazanonadecan-1-oic acid |
| (XXIV)819152-1-d | - | (5S,8S,11R,14S)-14-Amino-8-[4-[(tert-butoxycarbonyl)amino]butyl]-11-[(4-tert-butoxyphenyl)methyl]-18,18-dimethyl-4,7,10,13,16-pentaoxo-5-[3-[N'-(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-sulfonyl)carbamimidamido]propyl]-6,17-dioxa-3,9,12-triazanonadecan-1-oic acid |
| (XXV)819152-1-d | - | tert-Butyl [(2S,5R,8S,11S)-8-[4-[(tert-butoxycarbonyl)amino]butyl]-5-[(4-tert-butoxyphenyl)methyl]-3,6,9,12,15-pentaoxo-11-[3-[N'-(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-sulfonyl)carbamimidamido]propyl]-1,4,7,10,13-pentaazacyclopentadecan-2-yl]acetate |
Frequently asked questions
What are the approved indications of cRGD-ZW800-1?
Approved indications include: Head and neck squamous cell carcinoma, Cholangiocarcinoma, Pancreatic cancer.
When does the cRGD-ZW800-1 patent expire?
No public expiry year is available for cRGD-ZW800-1 yet; this page updates once verified.
How many synthesis routes are recorded for cRGD-ZW800-1?
4 synthesis routes are recorded; the shortest is 2 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy cRGD-ZW800-1 intermediates?
All intermediates in cRGD-ZW800-1 routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for cRGD-ZW800-1 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03